The HER2-Negative Breast Cancer Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size of HER2-negative breast cancer has experienced significant growth lately. The market value is projected to increase from $16.29 billion in 2024 to $17.62 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.1%.
The HER2-negative breast cancer market is predicted to expand to $23.86 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%.
Download Your Free Sample of the 2025 HER2-Negative Breast Cancer Market Report and Uncover Key Trends Now!The key drivers in the her2-negative breast cancer market are:
• Rising alcohol consumption
• Escalating adoption of unhealthy lifestyles
• Growing prevalence of obesity
• Increasing tobacco usage
The HER2-negative breast cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy
2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy
The key trends in the her2-negative breast cancer market are:
• One emerging trend is the innovation in diagnostic technologies.
• Targeted therapies are becoming increasingly integrated, indicating a new trend.
• The integration of immunotherapies is also seen as a significant emerging trend.
• FDA approvals and technological advancements are shaping the future of the market too.
Major players in the her2-negative breast cancer market are:
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Sanofi S.A.
• AstraZeneca PLC
• Novartis International AG
• Eli Lilly and Company
• Amgen Inc.
• Daiichi Sankyo Company Limited
• Jiangsu Hansoh Pharmaceutical Co. Ltd.
• BeiGene Ltd.
• Chipscreen Biosciences Ltd.
• F. Hoffmann-La Roche Ltd
• PharmAbcine Inc.
• Adagene Inc.
• H3 Biomedicine Inc.
• Radius Health Inc.
• Zenith Epigenetics Ltd.
North America was the largest region in the HER2-negative breast cancer market in 2024